News From The Journal Blood: January 10, 2013Main Category: Lymphoma / Leukemia / Myeloma
Also Included In: Genetics | Blood / Hematology
Article Date: 14 Jan 2013
Welcome to "This Week in Blood," a weekly snapshot of the hottest studies from each week's issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob L0wenberg, MD, and Deputy Editor Nancy Berliner, MD.
Systemic delivery of a TLR7 agonist in combination with radiation primes durable anti-tumor immune responses in mouse models of lymphoma
Dovedi et al.
This week's plenary paper offers a promising potential new immunotherapeutic modality for the treatment of lymphoma. The authors present convincing data to suggest that a toll-like receptor 7 (TLR7) agonist sensitizes tumor cells to radiotherapy. In a mouse model, this increases radiation-induced cell death and prolongs responses.
Model-based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia
Horn et al.
The success of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia (CML) has led to early investigation of the safety of discontinuing therapy for patients with prolonged deep response to treatment. In this manuscript, Horn and colleagues present a way of predicting the safety of therapy discontinuation.
Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms
Cazzola et al.
This manuscript, featured as this week's Perspective, discusses how our understanding of the pathophysiology of myelodysplastic syndromes (MDS) and other hematologic malignancies has been transformed over the last year with the discovery of the prevalence and prognostic significance of mutations in genes encoding the cellular splicing machinery.
Original article posted on Medical News Today.
Articles not to be reproduced without permission of Medical News Today